This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (30)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Rong-Fang Wang, MD; Janet B. Serle, MD; Steven M. Podos, MD; Michael F. Sugrue, PhD

Arch Ophthalmol. 1990;108(4):511-513.

Abstract
• L-671,152, a new potent water-soluble inhibitor of human carbonic anhydrase II in vitro, was applied topically to cynomolgus monkey eyes in which glaucoma had been produced by argon laser photocoagulation of the trabecular meshwork. Intraocular pressure was measured at 0 hours, 0.5 hours, and hourly for 8 hours in eight eyes for 2 baseline days, 1 day receiving the vehicle and 5 days receiving therapy with 2% L-671, 152 twice a day, after initial single-dose trials of various concentrations. Intraocular pressure was not significantly different comparing baseline and vehicle-treated days. Significant intraocular pressure reductions occurred from 1 to 8 hours after the first dose, and lasted for at least 16 hours after the second dose. The reduction in intraocular pressure became more pronounced from day 1 to day 5 at each time interval. The mean (± SEM) maximum reduction in intraocular pressure was 7.8 ± 2.1 mm Hg on day 1 and 10.1 ± 2.4 mm Hg on day 5 at 3 hours after administration, comparing the intraocular pressure in drug-treated and vehicle-treated eyes. L-671,152 has a longer duration of action than does previously studied MK-927 in glaucomatous monkeys. It appears to have great clinical potential.

Author Affiliations
From the Department of Ophthalmology, Mount Sinai School of Medicine, New York, NY (Drs Wang, Serle, and Podos), and Merck Sharp and Dohme, West Point, Pa (Dr Sugrue).

Footnotes
Accepted for publication November 3, 1989.

Reprint requests to the Department of Ophthalmology, Mount Sinai School of Medicine, One Gustave L. Levy Place, New York, NY 10029 (Dr Serle).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Effects of Dorzolamide on Choroidal Blood Flow, Ciliary Blood Flow, and Aqueous Production in Rabbits
Reitsamer et al.
IOVS 2009;50:2301-2307.
ABSTRACT | FULL TEXT  

Topical 2.0% Dorzolamide vs Oral Acetazolamide for Prevention of Intraocular Pressure Rise After Neodymium:YAG Laser Posterior Capsulotomy
Ladas et al.
Arch Ophthalmol 1997;115:1241-1244.
ABSTRACT  

Four-Week Safety and Efficacy Study of Dorzolamide, a Novel, Active Topical Carbonic Anhydrase Inhibitor
Wilkerson et al.
Arch Ophthalmol 1993;111:1343-1350.
ABSTRACT  

Dose Response and Duration of Action of Dorzolamide, a Topical Carbonic Anhydrase Inhibitor
Lippa et al.
Arch Ophthalmol 1992;110:495-499.
ABSTRACT  

MK-507 (L-671,152), a Topically Active Carbonic Anhydrase Inhibitor, Reduces Aqueous Humor Production in Monkeys
Wang et al.
Arch Ophthalmol 1991;109:1297-1299.
ABSTRACT  

Topically Active Carbonic Anhydrase Inhibitors for Glaucoma
Podos and Serle
Arch Ophthalmol 1991;109:38-40.
ABSTRACT